164 related articles for article (PubMed ID: 24091623)
1. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.
Bartlett JM; Brookes CL; Piper T; van de Velde CJ; Stocken D; Lyttle N; Hasenburg A; Quintayo MA; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix LY; Seynaeve C; Rea DW
Br J Cancer; 2013 Oct; 109(9):2453-61. PubMed ID: 24091623
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
3. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
4. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
Tovey S; Dunne B; Witton CJ; Forsyth A; Cooke TG; Bartlett JM
Clin Cancer Res; 2005 Jul; 11(13):4835-42. PubMed ID: 16000581
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
6. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
7. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Iddon J; Bundred NJ
Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
[TBL] [Abstract][Full Text] [Related]
8. Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
[TBL] [Abstract][Full Text] [Related]
9. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
11. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
12. Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.
Roseweir AK; Bennett L; Dickson A; Cheng K; Quintayo MA; Bayani J; McMillan DC; Horgan PG; van de Velde CJH; Seynaeve C; Hasenburg A; Kieback DG; Markopoulos C; Dirix LY; Rea DW; Mallon EA; Bartlett JMS; Edwards J
J Natl Cancer Inst; 2018 Jun; 110(6):616-627. PubMed ID: 29917140
[TBL] [Abstract][Full Text] [Related]
13. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
14. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
[TBL] [Abstract][Full Text] [Related]
16. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
19. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
[TBL] [Abstract][Full Text] [Related]
20. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
